

Stem Cell Therapy International, Inc.  
Form 8-K/A  
August 11, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): AUGUST 11, 2008 (August 5, 2008)**

**STEM CELL THERAPY INTERNATIONAL, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Nevada**  
(State or other jurisdiction of  
incorporation or organization)

**000-51931**  
(Commission File Number)

**2203 N. Lois Avenue, 9<sup>th</sup> Floor, Tampa, FL 33607**

**88-0374180**  
(I.R.S. Employer  
Identification No.)

Edgar Filing: Stem Cell Therapy International, Inc. - Form 8-K/A

(Address of principal executive offices - zip code)

(813) 600-4088

(Registrant's telephone number, including area code)

Not applicable

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

**ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.**

On July 14, 2008, Aidman, Piser & Company, P.A. ( Aidman Piser ) resigned as our independent registered public accounting firm. Aidman Piser's practice was acquired by Cherry, Bekaert & Holland, L.L.P. ( Cherry Bekaert ) in a transaction pursuant to which Aidman Piser merged its operations into Cherry Bekaert and certain of the professional staff and shareholders of Aidman Piser joined Cherry Bekaert either as employees or partners of Cherry Bekaert and will continue to practice as members of Cherry Bekaert.

The report of Aidman Piser regarding our financial statements for the fiscal year ended March 31, 2008 does not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles, except that substantial doubt was raised as to our ability to continue as a going concern. During the past year and during the period from the end of the most recently completed year through July 14, 2008, the date of resignation, there were no disagreements with Aidman Piser on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Aidman Piser would have caused it to make reference to such disagreements in its reports.

We provided Aidman Piser with a copy of the this Report and the report filed on Form 10-KSB (original notice of resignation) prior to filing it with the Securities and Exchange Commission and requested that Aidman Piser furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements set forth above (same statement as contained on the March 31, 2008 form 10KSB), if it does not agree, the respects in which it does not agree. A copy of the letter, dated July 14, 2008, was filed as Exhibit 10.30 to the form 10KSB filed on July 14, 2008.

On July 31, 2008 the Company engaged Brimmer, Burek, Keelan LLP, Certified Public Accountants, Tampa, FL, as its new independent accountants and who will audit the consolidated financial statements for the Company's Annual Report on Form 10K for the year ended March 31, 2009 and review the quarterly consolidated financial statements.

Exhibit:

- 10.30 Letter from Aidman Piser & Company, P.A. (Included as an exhibit to Registrant's Annual Report on Form 10-KSB for the year ended March 31, 2008 and incorporated herein by reference)

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEM CELL THERAPY INTERNATIONAL, INC.

By: /s/ Andrew J. Norstrud

Name: Andrew J. Norstrud

Title: Chief Financial Officer

Date: August 11, 2008